Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 13, 2007

SRI and Pentax to Advance Diagnostic Tool Development for Cancer

  • SRI International initiated a personalized medicine program to find cancer biomarkers to make diagnostic tools. This project is part of a multiyear collaboration with Pentax.

    Pentax will provide research funding and R&D milestone payments to SRI as well as royalties on sales of any resulting products.

    “Pentax and SRI are jointly addressing new opportunities in personalized medicine by developing diagnostic tools to assist in rapid and accurate selection of therapeutic options for treatment on an individual patient basis,” remarks Akira Yamamoto, research head at the Pentax Incubation Center and program director for the Pentax–SRI partnership.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »